Further supporting the immune-enhancing role of CCL3, Yuan et al. [54] revealed that DC-targeting chemokines inhibit CRC progression and state that CCL3 exhibits anti-tumor activities in vivo. The gene discussed is CCL3; the disease is neoplasm.